APA (7th ed.) Citation

Leng, Q., Zhou, J., Wang, X., Zhang, P., Xu, H., & Cao, D. (2025). HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: Study protocol of a single-arm, prospective phase Ib/II trial. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Leng, Qingqing, Jitao Zhou, Xin Wang, Pei Zhang, Huanji Xu, and Dan Cao. HRS-4642 Combined with Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma: Study Protocol of a Single-arm, Prospective Phase Ib/II Trial. Frontiers Media S.A, 2025.

MLA (9th ed.) Citation

Leng, Qingqing, et al. HRS-4642 Combined with Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma: Study Protocol of a Single-arm, Prospective Phase Ib/II Trial. Frontiers Media S.A, 2025.